News
IBIO
2.225
+1.14%
0.025
Weekly Report: what happened at IBIO last week (0406-0410)?
Weekly Report · 1d ago
iBio Is Maintained at Buy by Chardan Capital
Dow Jones · 5d ago
iBio Price Target Maintained With a $5.00/Share by Chardan Capital
Dow Jones · 5d ago
Ibio (IBIO) Receives a Buy from Chardan Capital
TipRanks · 5d ago
Validating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition
TipRanks · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
Reuters · 6d ago
BUZZ-iBio rises as obesity drug gets nod for human trial in Australia
Reuters · 6d ago
iBio Advances to Clinical Stage With IBIO-600 Trial
TipRanks · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Delta, Levi's, banks
Reuters · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Delta, GATX, Humana
Reuters · 6d ago
iBio receives regulatory clearance to initiate IBIO-600 trial in Australia
TipRanks · 6d ago
BUZZ-iBio rises as obesity drug gets first green light for human trial in Australia
Reuters · 6d ago
iBio wins Australian TGA clearance for Phase 1 IBIO-600 trial
Reuters · 6d ago
IBIO INC - PHASE 1 TRIAL OF IBIO-600 TO BEGIN DOSING IN Q2 2026
Reuters · 6d ago
IBIO RECEIVED REGULATORY CLEARANCE TO INITIATE ITS PHASE 1 CLINICAL TRIAL OF IBIO-600 IN AUSTRALIA
Reuters · 6d ago
Weekly Report: what happened at IBIO last week (0330-0403)?
Weekly Report · 04/06 10:00
Biotech Alert: Searches spiking for these stocks today
TipRanks · 03/30 16:21
Weekly Report: what happened at IBIO last week (0323-0327)?
Weekly Report · 03/30 10:01
Insiders Rock Asana, Ibio, Redwire, AFLAC, Sibanye Stillwater
TipRanks · 03/28 13:01
Top Ibio Insider Quietly Ups Stake in Bold New Bet
TipRanks · 03/28 02:01
More
Webull provides a variety of real-time IBIO stock news. You can receive the latest news about Ibio through multiple platforms. This information may help you make smarter investment decisions.
About IBIO
iBio, Inc. is a biotech company leveraging artificial intelligence and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. It has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.